AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil activation testing
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE/sIgG4 ratio
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara h 2 IgE
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara h 8 IgE
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: tIgE
Number of subjects: 67
Study 25841330 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgG4
Number of subjects: 67
Study 25841541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Mineral Content (BMC)
Number of subjects: 37
Study 25841541 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteocalcin (OCN)
Number of subjects: 37
Study 25841541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor 23 (FGF23)
Number of subjects: 37
Study 25841875 — intervention group
Group type: EXPERIMENTAL
Intervention: aMMP-8 test
Number of subjects: 60
Study 25844160 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week PATCH intervention + usual care
Number of subjects: 0
Study 25844160 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 25846031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤ 14 mg/24 h; dose adjustments ≤ 16 mg/24 h permitted)
Number of subjects: 87
Study 25846669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral TG1042 injection (adenovirus expressing IFN-γ) combined with tumor-infiltrating lymphocytes (TILs)
Number of subjects: 18
Study 25847227 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-based yttrium 90 therapy
Number of subjects: 30
Study 25847808 — intervention group
Group type: EXPERIMENTAL
Intervention: Assault-injury group (AIG)
Number of subjects: 349
Study 25847808 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 349
Study 25847808 — intervention group
Group type: EXPERIMENTAL
Intervention: AIG
Number of subjects: 349
Study 25847929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2) IV on days 1 and 8), Carboplatin (AUC 2 IV on days 1 and 8), Iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) administered every 21 days for four cycles (amended to six cycles).
Number of subjects: 80
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m(2) every 3 weeks)
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6 every 3 weeks)
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA-like genomic instability signature
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: p63/p73 expression status
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and PIK3CA mutation status
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 gene expression subtype
Number of subjects: 86
Study 25847936 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term responders
Number of subjects: 86
Study 25848412 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Health Records (EHRs)
Number of subjects: 328
Study 25848412 — intervention group
Group type: COMPARATOR
Intervention: Paper records
Number of subjects: 328
Study 25848948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (IVC) combined with chemotherapy
Number of subjects: 14
Study 25848948 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous vitamin C (IVC)
Number of subjects: 14
Study 25849228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 42
Study 25849571 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of sulfur-containing amino acids (SAAs), especially taurine
Number of subjects: 35
Study 25849571 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of cystine, taurine, and SAA levels
Number of subjects: 35
Study 25849571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores
Number of subjects: 35
Study 25849721 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times daily for ≥2 weeks
Number of subjects: 39
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: CHL1 rs4003413
Number of subjects: 459
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP43 rs283393 and rs9860828
Number of subjects: 459
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: ITGB3 rs3809865
Number of subjects: 459
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP43 molecular pathway
Number of subjects: 459
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: ELAVL4
Number of subjects: 459
Study 25850031 — intervention group
Group type: EXPERIMENTAL
Intervention: ITGB1 and NRP1
Number of subjects: 459
Study 25851633 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0
Study 25851633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25851633 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (crossover from placebo)
Number of subjects: 0
Study 25851633 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim/Pegfilgrastim
Number of subjects: 0
Study 25851633 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF primary prophylaxis
Number of subjects: 0
Study 25852054 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV reactivation
Number of subjects: 0
Study 25852166 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss after bariatric surgery (1 year post-surgery)
Number of subjects: 12
Study 25852820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Adriamycin-based chemotherapy with increased BFI scores (32 patients)
Number of subjects: 43
Study 25852820 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients without increased BFI scores)
Number of subjects: 43
Study 25852948 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch (NT) vein graft
Number of subjects: 65
Study 25852948 — intervention group
Group type: COMPARATOR
Intervention: Conventional (C) vein graft
Number of subjects: 65
Study 25852962 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal CO2 (EtCO2) monitoring using a dedicated naso-buccal sensor during non-invasive ventilation (NIV)
Number of subjects: 11
Study 25852962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and passive prolonged expiratory maneuvers
Number of subjects: 11
Study 25853713 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure (COP) in plasma
Number of subjects: 99
Study 25853713 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid osmotic pressure (COP) in interstitial fluid
Number of subjects: 99
Study 25853713 — intervention group
Group type: EXPERIMENTAL
Intervention: COP in interstitial fluid sampled from arm and leg
Number of subjects: 99
Study 25853713 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of prolonged implantation time on interstitial COP
Number of subjects: 99
Study 25853747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib at a daily dose of 420 mg
Number of subjects: 63
Study 25853841 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI measurement
Number of subjects: 110
Study 25853929 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable biliary stent (BDBS) insertion via endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 1
Study 25855120 — intervention group
Group type: EXPERIMENTAL
Intervention: δ(13)C value of finger-stick blood
Number of subjects: 257
Study 25855120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-isotope model (δ(13)C and δ(15)N)
Number of subjects: 257
Study 25855120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsweetener corn intake
Number of subjects: 257
Study 25855120 — intervention group
Group type: EXPERIMENTAL
Intervention: δ(15)N value
Number of subjects: 257
Study 25855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (recombinant FVIII-FS 20-30 IU/kg thrice weekly)
Number of subjects: 58
Study 25855376 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 58
Study 25855621 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death
Number of subjects: 519
Study 25855621 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral) in non-smokers with adenocarcinoma
Number of subjects: 519
Study 25855621 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, oral)
Number of subjects: 519
Study 25855668 — intervention group
Group type: EXPERIMENTAL
Intervention: PA:A>1 group
Number of subjects: 24
Study 25855668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Number of subjects: 24
Study 25855668 — intervention group
Group type: EXPERIMENTAL
Intervention: RV dysfunction and PA enlargement
Number of subjects: 24
Study 25855677 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra Transcatheter Pacing System
Number of subjects: 720
Study 25856269 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT) with low-dose hourly infusion of tissue plasminogen activator (tPA) or urokinase; average doses were 28.0 ± 11 mg tPA (n = 76) and 2,697,101 ± 936,287 International Units for urokinase (n = 23).
Number of subjects: 101
Study 25856269 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT)
Number of subjects: 101
Study 25856364 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-1 analogues
Number of subjects: 0
Study 25856364 — intervention group
Group type: COMPARATOR
Intervention: PAC-1
Number of subjects: 0
Study 25856540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea risk
Number of subjects: 1013
Study 25856540 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 1013
Study 25856540 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 1013
Study 25856546 — intervention group
Group type: EXPERIMENTAL
Intervention: botulinum toxin-A (BoNT-A) treatment
Number of subjects: 456
Study 25857307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 39
Study 25857307 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 39
Study 25858004 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25858045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-d imaging protocol (3.7-7.4 MBq/kg, followed by 11.1 MBq/kg)
Number of subjects: 78
Study 25858045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-d protocol (7.4 MBq/kg for both rest and stress)
Number of subjects: 78
Study 25858045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-d and 2-d protocols
Number of subjects: 78
Study 25858045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-d imaging protocol
Number of subjects: 78
Study 25858045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-d protocol
Number of subjects: 78
Study 25858498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab 1 mg/kg, 3 mg/kg, or 6 mg/kg intravenously on days 1/8/15 with doxorubicin 75 mg/m² as a 48 h infusion on day 1 of a 21 day cycle
Number of subjects: 30
Study 25858498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab alone after six cycles of combination therapy
Number of subjects: 30
Study 25858519 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term omeprazole therapy
Number of subjects: 812
Study 25858519 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term esomeprazole therapy
Number of subjects: 812
Study 25858519 — intervention group
Group type: COMPARATOR
Intervention: Anti-reflux surgery (ARS)
Number of subjects: 812
Study 25858543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic diaphragm biopsy technique
Number of subjects: 51
Study 25858543 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation biopsies
Number of subjects: 51
Study 25858543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic diaphragm biopsy without electrocoagulation
Number of subjects: 51
Study 25858546 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0
Study 25858546 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone ablation therapy
Number of subjects: 0
Study 25858546 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol replacement therapy
Number of subjects: 0
Study 25858546 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) correlation
Number of subjects: 0
Study 25858957 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0
Study 25858957 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 25858957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25859981 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based parametric response maps (PRM) of diffusion-weighted MRI and CT scans
Number of subjects: 0
Study 25860107 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 to 200 mg/day
Number of subjects: 798
Study 25860107 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 798
Study 25860107 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 798
Study 25860107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 25860203 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy administered by a specialized pediatric transport team
Number of subjects: 235
Study 25861036 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure, MyoGrip, MyoPinch, MoviPlate
Number of subjects: 23
Study 25861036 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoGrip, MyoPinch, MoviPlate
Number of subjects: 23
Study 25861217 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment selected to target a somatic mutation in the tumor
Number of subjects: 0
Study 25861217 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 25861285 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 75
Study 25861285 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 75
Study 25861285 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 25861459 — intervention group
Group type: EXPERIMENTAL
Intervention: ISM-High
Number of subjects: 0
Study 25861459 — intervention group
Group type: EXPERIMENTAL
Intervention: ISM-Low
Number of subjects: 0
Study 25861459 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 0
Study 25862255 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Performance Physical Battery
Number of subjects: 244
Study 25862255 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go test
Number of subjects: 244
Study 25862255 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Number of subjects: 244
Study 25862507 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned Group (AG)
Number of subjects: 104
Study 25862507 — intervention group
Group type: COMPARATOR
Intervention: Malaligned Group (MG)
Number of subjects: 104
Study 25862507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 25862508 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk motor control in patients with acute to subacute LBP (eyes-closed condition)
Number of subjects: 33
Study 25862508 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement precision in patients with acute to subacute LBP
Number of subjects: 33
Study 25862508 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported pain characteristics and fear of movement in patients with acute to subacute LBP
Number of subjects: 33
Study 25862561 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)-MRD
Number of subjects: 56
Study 25862561 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HCT NGS-MRD
Number of subjects: 56
Study 25862561 — intervention group
Group type: EXPERIMENTAL
Intervention: Any post-HCT NGS positivity
Number of subjects: 56
Study 25862561 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of detectable IgH-V(D)J NGS-MRD pre-HCT
Number of subjects: 56
Study 25862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) strain at atrial contraction (LASac)
Number of subjects: 146
Study 25862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Volume (LAV)
Number of subjects: 146
Study 25862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure
Number of subjects: 146
Study 25862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal Electromechanical Conduction Time
Number of subjects: 146
Study 25862716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LASac and Systolic Blood Pressure
Number of subjects: 146
Study 25864160 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants
Number of subjects: 6041
Study 25864160 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants in men
Number of subjects: 6041
Study 25864160 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of 45 CAD risk variants in individuals above median age of 45.11 years
Number of subjects: 6041
Study 25864295 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase enzyme replacement therapy (ERT)
Number of subjects: 1
Study 25865468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliovac (ERC 1671) administered intradermally with human GM-CSF (Leukine(®)), preceded by low-dose cyclophosphamide regimen.
Number of subjects: 9
Study 25865468 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care treatment).
Number of subjects: 9
Study 25867467 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44 μg subcutaneously three times weekly)
Number of subjects: 23
Study 25867537 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 838
Study 25867537 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 838
Study 25867537 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) reported at visit 1
Number of subjects: 838
Study 25867642 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based psycho-educational HIV/STI intervention
Number of subjects: 44
Study 25869032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed Video-Microscopy Analysis (HVMA)
Number of subjects: 203
Study 25869198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheatham Platinum stent
Number of subjects: 105
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 138
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS (threshold of 400)
Number of subjects: 138
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 138
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid (CACS/SPECT)
Number of subjects: 138
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid (coronary CTA/SPECT)
Number of subjects: 138
Study 25869350 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS (threshold 400)
Number of subjects: 138
Study 25869737 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography linked to mass spectrometry (GCMS)
Number of subjects: 484
Study 25869737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-reactive nanoarrays combined with pattern recognition
Number of subjects: 484
Study 25869867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T 1-hour algorithm
Number of subjects: 1320
Study 25870087 — intervention group
Group type: EXPERIMENTAL
Intervention: AUY922 (70 mg) and erlotinib (150 mg)
Number of subjects: 37
Study 25870087 — intervention group
Group type: EXPERIMENTAL
Intervention: AUY922 and erlotinib (doses not specified for phase II)
Number of subjects: 37
Study 25870329 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) - 3 doses at 1-month intervals, 1 additional dose 6 months later, followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later
Number of subjects: 251
Study 25870329 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 251
Study 25870329 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 251
Study 25870329 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose regimen of PCV13 followed by PPSV23
Number of subjects: 251
Study 25871496 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with ADHD
Number of subjects: 50
Study 25871496 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with ADHD treated with methylphenidate
Number of subjects: 50
Study 25871496 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 25872574 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloplast Titan IPP with NLMT and postoperative rehabilitation (daily inflation for 1 year)
Number of subjects: 40
Study 25872574 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation (daily inflation for 1 year)
Number of subjects: 40
Study 25872754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-delivered physical activity intervention during a 3-week run-in period using a mobile phone app and wearing a pedometer.
Number of subjects: 318
Study 25872754 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 318